Award Timing Disclosure

12 Months Ended

Dec. 31, 2024

Feb. 15, 2024

USD ($)

security

$ / shares

Award Timing Disclosures [Line Items]

Award Timing MNPI Disclosure

Policies and Practices Related to the Timing of Grants of Certain Equity Awards

AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year.

These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the highest and lowest trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2024 annual grant was $175.28. The high, low and closing prices of an AbbVie common share on the grant date (February 15, 2024) were $176.74, $173.81, and $176.59 respectively. All LTI awards are subject to a minimum vesting period of 12 months.

The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates. The following table presents information regarding option awards granted to our NEOs in the fiscal year ended December 31, 2024, during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such report with the SEC.

Award Timing Method

AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year.

These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the highest and lowest trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2024 annual grant was $175.28. The high, low and closing prices of an AbbVie common share on the grant date (February 15, 2024) were $176.74, $173.81, and $176.59 respectively. All LTI awards are subject to a minimum vesting period of 12 months.

Award Timing MNPI Considered

true

Award Timing, How MNPI Considered

The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates.

MNPI Disclosure Timed for Compensation Value

false

Awards Close in Time to MNPI Disclosures, Table

						Percentage
						change in the
						closing market
						price of the
						securities
						underlying the
						award between
						the trading day
						ending
						immediately
						prior to the
						disclosure of
						material
						nonpublic
						information and
						the trading day
						beginning
						immediately
						following the
		Number of	Exercise			disclosure of
		securities	price of the		Grant date fair	material
		underlying the	award		value of the	nonpublic
Name	Grant date	award	($/Share)		award	Information1
Robert A. Michael	2/15/2024	59,888	$	175.28	$1,888,269	(1.32)	%
Richard A. Gonzalez	2/15/2024	113,472	$	175.28	$3,577,772	(1.32)	%
Scott T. Reents	2/15/2024	31,520	$	175.28	$993,826	(1.32)	%
Jeffrey R. Stewart	2/15/2024	39,085	$	175.28	$1,232,350	(1.32)	%
Azita Saleki-Gerhardt	2/15/2024	29,313	$	175.28	$924,239	(1.32)	%
Timothy J. Richmond	2/15/2024	28,998	$	175.28	$914,307	(1.32)	%

(1) On February 20, 2024, the company reported its financial results for the fiscal year ended December 31, 2023 on Form 10-K.

Michael

Awards Close in Time to MNPI Disclosures

Name

Robert A. Michael

Underlying Securities | security

59,888

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 1,888,269

Underlying Security Market Price Change

(1.32)

Gonzalez

Awards Close in Time to MNPI Disclosures

Name

Richard A. Gonzalez

Underlying Securities | security

113,472

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 3,577,772

Underlying Security Market Price Change

(1.32)

Scott T. Reents

Awards Close in Time to MNPI Disclosures

Name

Scott T. Reents

Underlying Securities | security

31,520

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 993,826

Underlying Security Market Price Change

(1.32)

Jeffrey R. Stewart

Awards Close in Time to MNPI Disclosures

Name

Jeffrey R. Stewart

Underlying Securities | security

39,085

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 1,232,350

Underlying Security Market Price Change

(1.32)

Azita Saleki-Gerhardt

Awards Close in Time to MNPI Disclosures

Name

Azita Saleki-Gerhardt

Underlying Securities | security

29,313

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 924,239

Underlying Security Market Price Change

(1.32)

Timothy J. Richmond

Awards Close in Time to MNPI Disclosures

Name

Timothy J. Richmond

Underlying Securities | security

28,998

Exercise Price | $ / shares

$ 175.28

Fair Value as of Grant Date | $

$ 914,307

Underlying Security Market Price Change

(1.32)